Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

From Menace to Marvel

2009

Diabetes mellitus is a major risk factor for cardiovascular disease, and its prevalence is suspected to further increase in the coming years in the Western hemisphere and also in countries with emerging economies, like India, China, and Brazil. Together with the increasing prevalence of obesity and metabolic syndrome and the subsequent development of arterial hypertension, the epidemic of adiposity and diabetes mellitus may eat up most of the improvement of cardiovascular outcomes that we have seen within the last decades.1 The risk of atherosclerosis is inversely related to circulating levels of high-density lipoprotein (HDL) cholesterol. Results from the Framingham Study demonstrated that…

medicine.medical_specialtyApolipoprotein BbiologyCholesterolbusiness.industryReverse cholesterol transportTorcetrapibnutritional and metabolic diseasesmedicine.diseaseAngiotensin IIchemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineInternal Medicinemedicinebiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessLipoproteinHypertension
researchProduct

Estudio de los valores plasmáticos de Lp(a) en el defecto familiar de unión de la apo B 100 en una población mediterránea del sur de Europa

2004

Aims: 1) to study lipoprotein (a) (Lp(a)) plasma values in subjects with familial ligand-defective apo B 100 (FDB). Methods: We studied 19 heterozygous FDB subjects (8 males) from 12 families, carriers of R3500Q mutation on apo B gene and 90 controls (34 males). The genetic diagnosis was established with PCR-SSCP analysis and automatic sequencing. In all subjects plasma lipids, apoli-poprotein B and Lp(a) levels were determined with standard procedures. Results: Subjects carriers of R3500Q mutation on apo B gene have significantly higher plasma Lp(a) and log transformed Lp(a) values and prevalence of Lp(a) > 30 cut point for coronary heart disease than controls. Conclusions: Subjects with F…

medicine.medical_specialtyApolipoprotein Bbiologybusiness.industryCoronary heart diseaseEndocrinologyInternal medicinePlasma lipidsInternal Medicinebiology.proteinmedicineGenetic diagnosisbusinessLipoproteinAnales de Medicina Interna
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

Proteome alterations in aqueous humour of primary open angle glaucoma patients.

2019

Aim To unravel the primary open angle glaucoma (POAG) related proteomic changes in aqueous humour (AH). Methods Totally 35 patients listed for cataract surgery (controls: n=12, age: 67.4±13.6y) or trabeculectomy for POAG (n=23, age: 72.5±8.3y) were included. AH samples of those patients were obtained during cataract surgery or trabeculectomy. AH samples were subsequently pooled into the experimental groups under equal contribution in terms of protein amount of each individual patient. Protein samples were analyzed by a linear trap quadrupol Orbitrap Mass Spectrometry device with an upstream liquid chromatography system. The obtained raw data were analyzed using the Maxquant proteome softwar…

medicine.medical_specialtyApolipoprotein DOpen angle glaucomagenetic structuresmedicine.medical_treatmentGlaucomaproteomicslcsh:OphthalmologyOphthalmologyMedicineTrabeculectomywnt signaling pathwaybusiness.industryAqueous humourBrief ReportCataract surgerymedicine.diseaseFold changeprimary open angle glaucomaeye diseasesOphthalmologylcsh:RE1-994Proteomesense organsbusinessaqueous humorInternational journal of ophthalmology
researchProduct

Mild cognitive impairment: A systematic review

2007

MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can be divided into two broad subtypes: amnestic MCI ( aMCI) characterized by reduced memory, and non- amnestic MCI ( naMCI) in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD, while the outcomes of the naMCI subtypes appear more heterogeneous - including vascular dementia, frontotemporal dementia or dementia with Lewy bodies- but this aspect is still under debate. MCI in fact represents a condition with multiple sources of heterogeneity, including clinical presentation, etiology, and prognosis. To improve classifi…

medicine.medical_specialtyApolipoprotein E4Neuropsychological TestsSeverity of Illness Indexbehavioral disciplines and activitiesPhysical medicine and rehabilitationNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18Risk Factorsmental disordersEpidemiologySeverity of illnessmedicineHumansDementiaVascular dementiaapolipoprotein EAlzheimer disease; apolipoprotein E; biomarkers; diagnosis; mild congnitive impairmentMemory Disordersbusiness.industryDementia VascularGeneral NeuroscienceBrainCognitionGeneral Medicinemedicine.diseaseMagnetic Resonance Imagingmild congnitive impairmentdiagnosiPsychiatry and Mental healthClinical PsychologyEtiologybiomarkerSettore MED/26 - NeurologiaRadiopharmaceuticalsGeriatrics and GerontologyCognition DisordersbusinessFrontotemporal dementia
researchProduct

The lipoprotein lipase activity in cultured beating heart cells of the post-natal rat.

1974

Summary The lipoprotein lipase (LPL) activity was studied in cultured beating heart cells of the post natal rat as a function of the culture age, from the freshly trypsinized cell suspension up to the 14th day of culture. The LPL activity remains at a practically stationary level during the first four days of culture, and then increases rapidly to reach a plateau, at a level 3–4 times higher at the 21th day of culturing. The significance of this enzymatic activity progression comparing to 3H thymidine incorporation from the point of view of cell differentiation is discussed. Our results suggest that after the 12th day of culture, cells contain their optimal enzymatic apparatus for lipid met…

medicine.medical_specialtyBeating heartCellular differentiationBiologyTritiumBiochemistryInternal medicinemedicineAnimalsCells Culturedchemistry.chemical_classificationLipoprotein lipaseMyocardiumAge FactorsLipid metabolismHeartGeneral MedicineLipid MetabolismThymidine incorporationTrypsinizationRatsKineticsLipoprotein LipaseEndocrinologyEnzymechemistryAnimals NewbornPuromycinLipoprotein lipase activityThymidineBiochimie
researchProduct

Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism

2000

To induce dietary atherosclerosis in mice, high-fat/high-cholesterol (HF) diets are frequently supplemented with cholic acid (CA). This diet produces low plasma levels of high-density lipoprotein (HDL) and high levels of low-density lipoprotein (LDL). However, HF diets without any added CA, which more closely resemble human diets, increase levels of both HDL and LDL, suggesting that CA may be responsible for the lowering of HDL. Our aim was to examine the potential mechanism responsible for the lowering of HDL. Nontransgenic (NTg) C57BL mice and apoA-I-transgenic (apoAI-Tg) mice, with greatly increased basal apoA-I and HDL levels, were used. Mice were fed the following four diets: control (…

medicine.medical_specialtyBile acidmedicine.drug_classCholesterolResponse elementCholic acidnutritional and metabolic diseasesBiologyBiochemistrychemistry.chemical_compoundEndocrinologyHigh-density lipoproteinchemistryInternal medicineLow-density lipoproteinpolycyclic compoundsmedicinelipids (amino acids peptides and proteins)Hepatic lipaseLipoproteinEuropean Journal of Biochemistry
researchProduct

Impact of estrogens on atherosclerosis and bone in the apolipoprotein E-deficient mouse model.

2014

Objective The common inflammatory pathophysiology has nourished the hypothesis of a relationship between osteoporosis and cardiovascular disease. Estrogens are key agents in the modulation of both processes. We investigated whether induction of atherosclerosis affects bone and whether estrogens modulate both processes. Methods Female apolipoprotein E-deficient mice (a well-established model of atherogenesis) were ovariectomized or falsely operated and fed either standard diet or high-fat diet (HFD). Six animals were included in each of the four groups. To clarify mechanisms, we treated preosteoblastic MC3T3-E1 cells with mouse serum. Results Physiological levels of estrogens in falsely oper…

medicine.medical_specialtyBone densityApolipoprotein BOvariectomyOsteoporosisDiet High-FatBone resorptionMiceApolipoproteins EBone DensityTrabecular PatternInternal medicinemedicineAnimalsHumansBone ResorptionBone mineralbiologybusiness.industryObstetrics and GynecologyEstrogensmedicine.diseaseAtherosclerosisDisease Models AnimalEndocrinologymedicine.anatomical_structureOvariectomized ratbiology.proteinOsteoporosisCortical boneFemalebusinessMenopause (New York, N.Y.)
researchProduct

Do we need better lipid tools for cardiovascular risk assessment ?

2008

medicine.medical_specialtyCardiovascular diseases Dyslipidemia Lipoproteinsbusiness.industrymedicineGeneral MedicineIntensive care medicineRisk assessmentbusiness
researchProduct

3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke…

2017

AIMS: Relatively little is known about the health outcomes associated with very low plasma concentrations of high density lipoprotein cholesterol (HDL-C) mainly because of the small numbers of individuals with such extreme values included in clinical trials. We therefore investigated the association between low and very low HDL-C concentration at baseline and incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical And Racial Differences in Stroke (REGARDS) study. METHODS AND RESULTS: Analysis was based on 21,751 participants from the REGARDS study who were fre…

medicine.medical_specialtyCholesterolProportional hazards modelbusiness.industryHazard ratioDiseasemedicine.diseaseConfidence intervalchemistry.chemical_compoundHigh-density lipoproteinchemistryInternal medicinemedicineCardiology and Cardiovascular MedicinebusinessStrokeDyslipidemiaEuropean Heart Journal
researchProduct